

NASHAT Y. GABRAIL, M.D.

Oncologist/Hematologist

OFFICE

4875 Higbee Ave NW - Canton, Ohio 44718

Phone (330) 492-3345

PERSONAL DATA

Born March 21, 1952 - Neneveh, Iraq

QUALIFICATIONS

- M.D. - Mosul College of Medicine, 1976
- M.R.C.P. - Member of the Royal College of Physicians, United Kingdom, 1982
- MRCPATH - Member of the Royal College of Pathologists, London, 1984
- Member of the American Board of Internal Medicine, 1987
- Member of the American Board of Medicine (Oncology), 1989

EXPERIENCE

- 2022 – Present The Gabrail Pharmacology Phase 1 Research Center, Canton, Ohio
Phase 1 Healthy Volunteer and Cancer Clinic
President and Medical Director
- 2015 – Present Clinical Research Trials, Canton, Ohio
Phase 1 CRU
President and Medical Director
- 2014 – Present Sargon Research, Canton, Ohio
Site Management Organization
President and Medical Director
- 2013 – Present EHCS Employer Health Care Savings
On-Site Health Clinics
Co-Founder and Medical Director
- 1990 - Present Gabrail Cancer Center, Canton, Ohio
President
- 1988 - 1990 St. Louis University Hospital, St. Louis, Missouri
Assistant Professor of Medicine, Division of Hematology/Oncology and BMT
- 1987 – 1988 University of Missouri Hospital and Clinics, Columbia, Missouri
Fellow in Hematology/Oncology
- 1985 – 1987 Hurley Medical Center, Flint, Michigan
Resident, Internal Medicine
- 1983 – 1984 Southern General Hospital, Glasgow, Scotland
Registrar, Department of Hematology
- 1981 – 1983 Western General Hospital, Edinburg, Scotland
Registrar, Department of Hematology

Nashat Y Gabrail, M.D.

1977 – 1980 University of Saladin Irbil, Iraq
Lecturer in Hematology and Pathology

1976 – 1977 Medical City of Baghdad, Iraq
Internship

SPECIAL EXPERIENCE

1990 – Present Gabrail Cancer Center, Canton, Ohio
Industry Sponsored Clinical Trials
Specializing in Bioequivalence, Phase 0, and Phase 1 Oncology Studies

1989 Fred Hutchinson Cancer Center, Seattle, Washington
Three months' sabbatical in Bone Marrow Transplantation

1984 West of Scotland Transfusion Center, Carlouk, Scotland
Two weeks of intensive training in Blood Banking and Blood Transfusion, Monitoring the safety of blood products

AWARDS/ACKNOWLEDGEMENTS

2017- Present Host of Radio Podcast; The Cancer Gene on iHeartRadio, WHLO

2017 Host of Radio Podcast; Good Medicine is Cheaper Medicine, WHBC

2016 Author; The Cancer Gene

2009 Author; Good Medicine is Cheaper Medicine

2008 “Best Small Oncology Practice in Patient care”; Hematology Oncology News and Issues, (HOPE)

2008 “Best Facility Design”; Hematology Oncology News and Issues, (HOPE)

2008 “Best Small Oncology Practice in Revenue Strategy”; Hematology Oncology News and Issues, (HOPE)

2008 “Business of Excellence” Award, Greater Canton Chamber of Commerce

2008 “Clinical Best Practice Award”; Hematology Oncology News and Issues, (HOPE)

2008 ASCO Foundation Community Oncology Research Award Nominee by the Ohio West Virginia Oncology Society

2004 Recognized as one of the top 400 research centers in the world by PRA International

ORGANIZATION MEMBERSHIPS

2010 – Present Member of the Board of Advisors, International Oncology Network; ION Solutions, Frisco, TX

2014 – Present Trustee of OHOS (Ohio Hematology Oncology Society)

2015 – Present Board Member COA (Community Oncology Alliance)

2015 - Present Member of CCTA (Coalition of Clinical Trial Awareness), Board of Directors

Nashat Y Gabrail, M.D.

- 2015 - Present Member Heron Therapeutics STUSTOL Steering Committee
- 2012 – Present Member of the Board of Directors, Aultman Cancer Center of Excellence, LLC, Canton, Ohio
- 2007 – 2011 Past Member of the Editorial Board for Hematology & Oncology News and Issues (HONI)
- 2000 – 2006 Past President, Assyrian Medical Society
- 1984 Member of the Royal College of Physicians and Edinburgh, UK
- 1982 Member of the Royal College of Pathologists of London, UK
- 2003 – Present Consultant for CRO's and Pharmaceutical Industry in the design and writing of Clinical Protocols
- 2006 – Present Columnist for regional newspapers (The Repository, The Times-Reporter, The Observer, and The Budget)

PUBLICATIONS

- **Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma**
Cara Haymaker, Daniel H Johnson, Ravi Murthy, Salah-Eddine Bentebibel, Marc I Uemura, Courtney W Hudgens, Houssein Safa, Marihella James, Robert HI Andtbacka, Douglas B. Johnson, Montaser Shaheen, Michael A. Davies, Shah Rahimian, Srinivas K Chundururu, Denai R. Milton, Michael T. Tetzlaff, Willem W Overwijk, Patrick Hwu, Nashat Gabrail, Sudhir Agrawal, Gary Doolittle, Igor Puzanov, Joseph Markowitz, Chantale Bernatchez and Adi Diab
Cancer Discovery, March 11 2021, DOI:10.1158/2159-8290.CD-20-1546
- Jonathan W. Goldman, Terrence L. Fisher, Elizabeth Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Andreas Schroder, Kevin Chin, Michael Shafique, Thaddeus Beck, Megan A. Baumgart, Ramaswamy Govindan, **Nashat Gabrail**, Rachel E. Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, and Maurice Zauderer, **Interim results from CLASSICAL-Lung, phase 1b/2 Study of pepinemab (VX15/2503) in combination with Avelumab in advanced NSCLC**, AACR Poster Abstract, April 24 2020
- Jason Gotlib, MD, MS¹, **Nashat Gabrail, MD²**, Casey L. O'Connell, MD³, Regina Garcia-Delgado, MD⁴, Timothy Sbardellati⁵, Wayne M. Rothbaum⁵, Jesse McGreivy⁵, Claire N Harrison, Professor⁶ and Jean-Jacques Kiladjian, MD, PhD⁷, ¹Stanford Cancer Institute, Stanford, CA, ²**Gabrail Cancer Center, Canton, OH**, ³Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁴Hospital Universitario Virgen de la Victoria, Málaga, Spain, ⁵Kartos Therapeutics, Inc., Redwood City, CA, ⁶Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom, ⁷Hôpital Saint Louis & Université de Paris, Paris, France, **A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera**, ASH Poster Abstract, December 9, 2019
- Lee Rachel E Sanborn¹, **Nashat Y Gabrail²**, Nina Bhardwaj³, Michael Gordon⁴, Mark O'Hara⁵, Danny Khalil⁶, Thomas Hawthorne⁷, Richard Gedrich⁷, Laura Vitale⁷, Mark Rogalski⁷, Tianshu Li⁷, Tracey Rawls⁷, Tibor Keler⁷, Michael Yellin⁷, 1. Earle A Chiles Research Institute, Portland, OR 2. **Gabrail Cancer Center, Canton, OH** 3. Icahn School of Medicine at Mount Sinai, New York, NY 4. Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, AZ 5. Hospital of the University of Pennsylvania, Philadelphia, PA 6. Memorial Sloan Kettering Cancer Center,

New York, NY 7. Celldex Therapeutics, INC., Hampton, NJ, **First in Human Phase 1 Study of the CD40 Agonist Monoclonal Antibody (mAb) CD-1140 Alone and in Combination with CDX-301 (rhFLT3L) in Patients with Advanced Cancers: Interim Results**, AACR Poster Abstract, April 2, 2019

- Lee S Schwartzberg¹, Trent McLaughlin², Robert B Geller³, **Nashat Y Gabrail⁴** & Stanley Marks⁵, ¹Division of Hematology/Oncology, Department of Medicine, University of Tennessee Health Sciences Center and West Cancer Center, 7945 Wolf Rover Blvd, Germantown, TN 38138, USA, ²Real-World Evidence, Xcenda LLC, 4114 Woodlands Parkway, Suite 402, Palm Harbor, FL 34685, USA, ³Medical Affairs, heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA, ⁴Department of Oncology, Gabrail Cancer Center, 4875 Higbee Ave NW, Canton, Ohio 44718, USA, ⁵UPMC Hilman Cancer Center, 5150 Centre Ave, 5th Floor Cancer Pavilion, Pittsburgh, Pa 15232. **Real world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy**, *Journal of Comparative Effectiveness Research*, October 11, 2018
- Florence Atrafi, Harry Groen, Lauren Byers, Elena Garralda, Martjin Lolkema, Randeep Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, **Nashat Gabrail**, Beibei Hu, Tian Y Tian, Silpa Nuthalapati, Elizabeth Hoening, Lei He, Philip Komarnitsky, and Antonio Calles, **A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors**, *Clinical Cancer Research*, Manuscript # CCR-18-2014R1, October 10, 2018
- Maria Victoria Mateos*¹, Albert Oriol Rocafiguera², Paula Rodríguez Otero³, Joan Bladé⁴, Alessandra Larocca⁵, Jan S. Moreb⁶, Adrián Alegre⁷, Michele Cavo⁸, Hani Hassoun⁹, Amitabha Mazumder¹⁰, Christopher Maisel¹¹, Agne Paner¹², **Nashat Gabrail¹³**, Kathleen Halka¹⁴, Jeffrey Zonder¹⁵, Enrique M. Ocio¹, Catriona Byrne¹⁶, Johan Harmenberg¹⁶, Eva Nordstrom¹⁶, Sara Thuresson¹⁶, Hanan Zubair¹⁶, Paul Richardson¹⁷ ¹Hospital Clinico Universitario de Salamanca, Salamanca, ²ICO Badalona -Hospital Germans Trias i Pujol, Badalona, ³Clinica Universidad de Navarra, Pamplona, ⁴Servicio de Onco-Hematologia, Hospital Clinica de Barcelona, Barcelona, Spain, ⁵Ematologia U., A.O.U. Città della Salute e della Scienza di Torino-S.C., Torino, Italy, ⁶UF Health Shands Cancer Hospital, Gainesville, FL, United States, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Policlinico S. Orsola Malphigi, Bologna, Italy, ⁹Memorial Sloan Kettering Cancer Center, New York, ¹⁰Hudson Valley Hematology & Oncology Associates RLLP, Hawthorne, NY, ¹¹Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX, ¹²Rush University Medical Center, Chicago, IL, ¹³**Gabrail Cancer Center Research, Canton, OH**, ¹⁴Scott & White Memorial Hospital and Clinic, Temple, TX, ¹⁵Karmanos Cancer Institute, Detroit, MI, United States, ¹⁶Oncopeptides AB, Stockholm, Sweden, ¹⁷Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA: **Preliminary Report on Efficacy and Safety of Melflufen in Late Stage Relapsed-Refractory Myeloma (RRMM) Patients Refractory to Pomalidomide and/or Daratumumab**. EHA 2018, Oral Abstract, June 2018
- **Nashat Gabrail**,¹ Ronald Yanagihara,² Marek Spaczyński,³ William Cooper,⁴ Erin O'Boyle,⁵ Carrie Smith,¹ and Ralph Boccia⁶ ¹**Gabrail Cancer Center, Canton, OH, USA**, ²St Louise Regional Hospital, Gilroy, CA, USA, ³Department of Gynecology, Obstetrics and Gynecologic Oncology, University of Medical Sciences, Poznan, Poland, ⁴TFS International, Flemington, NJ, USA, ⁵FibroGen, Inc., San Francisco, CA, USA, ⁶Center for Cancer and Blood Disorders, Bethesda, MD, USA: **Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials**. *Cancer Manag Res*. Volume 7. March 2015

- John Kuruvilla, MD¹, John C. Byrd, MD², Joseph M Flynn³, Ramiro Garzon, MD³, Pierluigi Porcu, MD⁴, Nina Wagner-Johnston⁵, Mary Lynn Savoie, MD, FRCPC⁶, Richard M. Stone, MD⁷, Eric D. Jacobsen, MD⁷, Morten Mau-Sorensen, MD⁸, Peter de Nully Brown⁹, Rachid Baz, MD¹⁰, Bijal Shal, MD¹¹, Ian Flinn¹², **Nashat Gabrail, MD¹³**, Vishal Kukreti, MD¹⁴, Rodger E. Tiedemann, MD, PhD¹⁴, Yosef Landesman, PhD¹⁵, Boris Klebanov, M.A., MSc¹⁵, Eran Shacham, PhD¹⁵, Jean-Richard Saint-Martin¹⁶, Tracey Marshall¹⁶, John McCartney, PhD¹⁷, Dilara McCauley, PhD¹⁵, Robert Carlson, PhD¹⁵, Sasha Norori, MSc¹⁸, Michael R Savona, MD¹⁶, Tami Rashal, MD¹⁵, Mansoor R Mirza, MD¹⁶, Michael Kauffman, MD, PhD¹⁵ and Sharon Shacham, PhD, MBA¹⁵ ¹Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada ²The Ohio State University Medical Center, Columbus, OH ³The Ohio State University Comprehensive Cancer Center, Columbus, OH ⁴Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH ⁵Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO ⁶Alberta Health Services, Calgary, AB, Canada ⁷Dana-Farber Cancer Institute, Boston, MA ⁸Department of Oncology Rigshospitalet, Copenhagen, Denmark ⁹Department of Oncology, Rigshospitalet, Copenhagen, Denmark ¹⁰Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL ¹¹H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL ¹²Sarah Cannon Research Institute, Nashville, TN ¹³**Gabrail Cancer Center, Canton, OH** ¹⁴Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada ¹⁵Karyopharm Therapeutics, Inc, Newton, MA ¹⁶Karyopharm Therapeutics, Newton, MA ¹⁷Karyopharm Therapeutics Inc, Newton, MA ¹⁸Ozmosis Research Inc., Toronto, ON, Canada: **The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL).** ASH 2014. Oral Presentation. December 2014
- Parameswaran N. Hari, MD¹, Kenneth H. Shain, MD, PhD², Peter M. Voorhees, MD³, **Nashat Gabrail, MD⁴**, Muneer H. Abidi, MD⁵, Jeffrey Zonder, MD⁵, Ralph V. Boccia, MD⁶, Paul G. Richardson⁷, Linda L. Neuman, MD, MBA⁸, Sandra J. Dixon, MS⁹ and Claudia Paba Prada, MD¹⁰ ¹Department of Medicine, Medical College of Wisconsin, Milwaukee, WI ²H. Lee Moffitt Cancer Center, Tampa, FL ³Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC ⁴Gabrail Cancer Center, Canton, OH ⁵Wayne State University, Karmanos Cancer Center, Detroit, MI ⁶Center for Cancer and Blood Disorders, Bethesda, MD ⁷The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ⁸Onyx Pharmaceuticals, Inc., Redwood City, CA ⁹Onyx Pharmaceuticals, Inc., South San Francisco, CA ¹⁰Dana-Farber Cancer Institute, Boston, MA: **Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study.** ASH 2014. Oral and Poster Abstract. December 2014
- Christine I. Chen, MD, MEd, FRCPC¹, Martin Gutierrez, MD², David S. Siegel, MD, PhD², Joshua R. Richter, MD³, Nina Wagner-Johnston⁴, Craig C Hofmeister, MD, MPH⁵, Jesus G. Berdeja, MD⁶, **Nashat Gabrail, MD⁷**, Rachid Baz, MD⁸, Morten Mau-Sorensen, MD⁹, Suzanne Trudel, MD, MSc, FRCPC¹⁰, Rodger E. Tiedemann, MD, PhD¹, Vishal Kukreti, MD¹, Nuchanan Areethamsirikul, MD¹¹, Asfar Azmi, PhD¹², Trinayan Kashyap, MSc¹³, Yosef Landesman, PhD¹³, Tracey Marshall¹⁴, John McCartney, PhD¹⁵, Jean-Richard Saint-Martin¹⁴, Sasha Norori, MSc¹⁶, Michael R Savona, MD¹⁴, Tami Rashal, MD¹³, Robert Carlson, PhD¹³, Mansoor R Mirza, MD¹⁴, Sharon Shacham, PhD, MBA¹³, Michael Kauffman, MD, PhD¹³ and Donna E Reece, MD, FRCPC¹ ¹Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada ²John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ ³John Theurer Cancer Center, Hackensack University Medical Center,

Hackensack, NJ ⁴Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO ⁵Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH ⁶Sarah Cannon Research Institute, Nashville, TN ⁷**Gabrail Cancer Center, Canton, OH** ⁸Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL ⁹Rigshospitalet, Copenhagen, Denmark ¹⁰Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada ¹¹Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada ¹²Pathology, Wayne State University / Karmanos Cancer Institute, Detroit, MI ¹³Karyopharm Therapeutics, Inc, Newton, MA ¹⁴Karyopharm Therapeutics, Newton, MA ¹⁵Karyopharm Therapeutics Inc, Newton, MA ¹⁶Ozmosis Research Inc., Toronto, ON, Canada: **Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)**. ASH 2014. Oral and Poster Abstract. December 2014

- Harry Raftopoulos¹, William Cooper², Erin O'Boyle³, **Nashat Gabrail⁴**, Ralph Boccia⁵, Richard J Gralla⁶; (1)Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Lake Success, NY, 11042, USA, (2)TFS International, 70 Church St, Flemington, NJ 08822, USA, (3)FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA, **(4)Gabrail Cancer Center, 4875 Higbee Avenue NW, Canton, OH 44718, USA**, (5)Center for Cancer and Blood Disorders, 6410 Rockledge Drive #660, Bethesda, MD 20819, USA, (6)Albert Einstein College of Medicine, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA. **Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.** *Support Care Cancer*. 2014 Sep 2. Epub 2014 Sep 2
- J. Martignetti¹, A.R.A. Razak², Y. Chen³, **N.Y. Gabrail⁴**, J.F. Gericitano⁵, C. Camacho³, E. Pereira³, B. Evans¹, P. Dottino¹, D. McCauley⁶, S. Shacham⁶, T. Rashal⁶, J. Saint-Martin⁶, E. Shacham⁶, D. Vincent⁷, M. Kauffman⁶, M.R. Mirza⁶, M. Mau-Sorensen⁸ (1) Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY (2) Drug Development Program, Princess Margaret Cancer Center, Toronto, Canada; **(3) Gabrail Cancer Center, Canton, OH, USA**; (4) Memorial Sloan Kettering Cancer Center, New York, NY, USA; (5) Karyopharm Therapeutics Inc, Newton, MA, USA; (6) Ozmosis Research Inc, Toronto, Canada; (7) Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark: **Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE™) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa)**. ESMO 2014, Abstract 7042, *Annals of Oncology* (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338, Poster, September 2014
- H. Mahaseth¹, S.N. Maity², **N.Y. Gabrail³**, A. Mahipal⁴, J.F. Gericitano⁵, S. Shacham⁶, T. Rashal⁷, B. Klebanov⁷, R. Carlson⁶, E. Shacham⁷, D. Vincent⁸, M. Kauffman⁷, A.F. Shields⁹, M.R. Mirza⁶, J.C. Araujo¹⁰ (1) Karmanos Cancer Center, Wayne State University, 48201 - Detroit/US (2) Memorial Sloan Kettering Cancer Center, New York/US **(3) Gabrail Cancer Center, Canton/US** (4)Medical Oncology (4) Moffitt Cancer Center, 33612 - Tampa/US (5) Memorial Sloan Kettering Cancer, New York/US (6) Karyopharm Therapeutics, Inc., 01760 - Natick/US (7) Karyopharm Therapeutics, 01760 - Natick/US (8) Ozmosis Research, Toronto/CA (9)Oncology, Karmanos Cancer Center, Wayne State University, 48201 - Detroit/US (10) MD Anderson Cancer Center, Houston/US: **Selinexor (KPT-330), an oral, selective inhibitor of nuclear export (SINE) shows anti-prostate cancer (PrCa) activity preclinically & disease control.** ESMO 2014, *Annals of Oncology* (2014) 25 (suppl_4): iv255-iv279. 10.1093/annonc/mdu336, Poster, September 2014
- A. Mahipal¹, **N.Y. Gabrail²**, A. Sukari³, H. Mahaseth³, M. Mau-Sorensen⁴, S. Shacham⁵, J. Saint-

Martin⁶, S. Friedlander⁵, Y. Landesman⁶, J. Ellis⁶, E. Shacham⁶, J. McCartney⁶, T. Marshall⁶, D. Vincent⁷, T. Rashal⁶, M. Kauffman⁶, M.R. Mirza⁶, A.R.A. Razak⁸ (1) Moffitt Cancer Center, Tampa, FL, USA; (2) **Gabraïl Cancer Center, Canton, OH, USA**; (3) Karmanos Cancer Institute, Detroit, MI, USA; (4) Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark; (5) Karyopharm Therapeutics Inc, Newton, MA, USA; (6) Ozmosis Research Inc., Toronto, Canada (7) Drug Development Program, Princess Margaret Cancer Center, Toronto, Canada: **Clinical activity of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with head & neck squamous cell carcinoma.** ESMO 2014, *Annals of Oncology* (2014) 25 (suppl_4): iv340-iv356. 10.1093/annonc/mdu340, Poster, September 2014

- Dariusz Wydra¹, Sharad Anat Ghamande², **Nashat Gabrail**³, Elzbieta Nowara⁴, Mariusz Bidzinski⁵, Stephen DePasquale⁶, Romnee Clark⁷, Richard T. Penson⁸; (1)Dept of Gynecology, Gynecological Oncology, and Gynecological Endocrinology, Medical University of Gdansk, Gdansk, Poland; (2)Georgia Regents University, Augusta, GA, USA; (3)**Gabraïl Cancer Center, Canton, OH, USA**; (4)Cancer Center and Institute Gliwice Branch, Gliwice, Poland; (5)Specialist Hospital 'Inflancka', Department of Gynecological Oncology, Warsaw, Poland; (6)Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA; (7)Endocyte, Inc, West Lafayette, IN, USA; (8)Massachusetts General Hospital, Boston, MA, USA: **PRECEDENT Subset Analysis: Safety and Disease Control with Vintafolide Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (PLD).** ESMO 2014, *Annals of Oncology* (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338, Poster, September 2014
- Dariusz Wydra¹, Sharad Anat Ghamande², **Nashat Gabrail**³, Elzbieta Nowara⁴, Mariusz Bidzinski⁵, Stephen DePasquale⁶, Romnee Clark⁷, Richard T. Penson⁸ (1)Dept of Gynecology, Gynecological Oncology, and Gynecological Endocrinology, Medical University of Gdansk, Gdansk, Poland; (2)Georgia Health Sciences University, Augusta, GA, USA; (3)**Gabraïl Cancer Center, Canton, OH, USA**; (4)Cancer Center and Institute Gliwice Branch, Gliwice, Poland; (5)Specialist Hospital 'Inflancka', Department of Gynecological Oncology, Warsaw, Poland; (6)Chattanooga's Program in Women's Oncology, Chattanooga, TN, USA; (7)Endocyte, Inc, West Lafayette, IN, USA; (8)Massachusetts General Hospital, Boston, MA, USA: **Vintafolide and its Companion Imaging Agent, Etarfolatide – Results From a PRECEDENT Subanalysis.** EANM abstract, Poster, August 2014
- Nancy U. Lin, **Nashat Y. Gabrail**, John Sarantopoulos, Lee Steven Schwartzberg, Santosh Kesari, Susan Elaine Bates, Carey K. Anders, Anthony D. Elias, Jean-Paul Castaigne, Vihra Iordanova, Betty Lawrence, Razelle Kurzrock; Dana-Farber Cancer Institute, Boston, MA; **Gabraïl Cancer Center, Canton, OH**; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX; The University of Tennessee Health Science Center, Memphis, TN; University of California, San Diego, La Jolla, CA; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of Colorado Cancer Center, Aurora, CO; Angiochem, Inc., Montreal, QC, Canada; Angiochem Inc., Montreal, QC, Canada: **Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors.** 2014 ASCO Annual Meeting, Abstract 2523, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 2523), Poster, 2014
- John Martignetti, Albiruni R.A. Razak, Ying Chen, **Nashat Y. Gabrail**, John F. Gerecitano, Catalina Camacho, Elena Pereira, Peter Remsen Dottino, Sharon Shacham, Dilara McCauley, Tami Rashal, Jean-Richard Saint-Martin, Eran Shacham, Darcy Vincett, Michael Kauffman, Mansoor Raza Mirza, Morten Sorensen; Mount Sinai School of Medicine, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; **Gabraïl Cancer Center, Canton, OH**; Memorial Sloan-Kettering Cancer Center, New York, NY; Mt Sinai Medical Center, New York,

NY; Karyopharm Therapeutics, Newton, MA; Ozmosis Research, Toronto, ON, Canada; Rigshospitalet, Copenhagen, Denmark: **Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).** 2014 ASCO Annual Meeting, Abstract 5522, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5522), Poster, 2014

- Karen W. L. Yee, Michael Savona, Morten Sorensen, Peter Brown, William G. Blum, Daniel J. DeAngelo, Martin Gutierrez, Ramiro Garzon, Andre C. Schuh, **Nashat Y. Gabrail**, Martha Wadleigh, Jeffrey E. Lancet, Bijal D. Shah, Jesus G. Berdeja, Nina D. Wagner-Johnston, Ian Flinn, Tami Rashal, Michael Kauffman, Sharon Shacham, Richard M. Stone; Princess Margaret Cancer Center, Toronto, ON, Canada; Tennessee Oncology, Nashville, TN; Rigshospitalet, Copenhagen, Denmark; H:S Rigshospitalet, The Finsen Centre, KAT, Hematology Department 4241, Copenhagen, Denmark; The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; John Theurer Cancer Center, Hackensack, NJ; **Gabrail Cancer Center, Canton, OH**; Dana-Farber Cancer Institute, Harvard University, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Sarah Cannon Research Institute, Nashville, TN; Washington University School of Medicine in St. Louis, St. Louis, MO; Karyopharm Therapeutics, Newton, MA: **A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).** 2014 ASCO Annual Meeting, Abstract 7032, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 7032), Poster, 2014
- Gilles A. Salles, Nicole Lamanna, Bipinkumar R. Amin, Ralph V. Boccia, **Nashat Y. Gabrail**, Muhammad-Ali A. Zaydan, Michelle Wong, Adeboye H. Adewoye, Paolo Ghia; Lyon Sud University Hospital, Pierre-Bénite, France; Memorial Sloan Kettering Cancer Center, New York, NY; Mid Dakota Clinic, Bismarck, ND; Center for Cancer and Blood Disorders, Bethesda, MD; **Gabrail Cancer Center, Canton, OH**; Montgomery Cancer Center, Mt. Sterling, KY; Gilead Sciences, Foster City, CA; Università Vita e Salute; San Raffaele Scientific Institute, Milano, Italy: **A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.** 2014 ASCO Annual Meeting, Abstract TPS7123, *J Clin Oncol* 32:5s, 2014 (suppl; abstr TPS7123), Poster, 2014
- Tomasz M. Beer, Sebastien J. Hotte, Johann Sebastian De Bono, Philippe Beuzeboc, **Nashat Y. Gabrail**, Daniel Cain, Cindy Jacobs, Karim Fizazi; Oregon Health & Science University-Knight Cancer Institute, Portland, OR; Juravinski Cancer Centre, Hamilton, ON, Canada; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Medical Oncology Department, Institut Curie, Paris, France; **Gabrail Cancer Center, Canton, OH**; OncoGenex Pharmaceuticals, Inc., Bothell, WA; Institut Gustave Roussy, University of Paris, Villejuif, France: **Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.** 2014 Genitourinary Cancer Symposium, Abstract 222; *J Clin Oncol* 32, 2014 (suppl 4; abstr 222), Poster, 2014
- Eric Laille¹, Sanjay Goel², Alain C. Mita³, **Nashat Y. Gabrail⁴**, Kevin Kelly³, Liangang Liu¹, Stephen Songer¹ and Charles L. Beach¹; (1) Celgene Corporation, Summit, New Jersey; (2) Monteliore Einstein Cancer Center, Bronx, New York; (3) CTRC at the University of Texas Health Science Center, San Antonio, Texas; (4) **Gabrail Cancer Center, Canton, Ohio: A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.** *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* Volume 34: Issue 5 pgs 440-451. May 2014

- Carrie Smith, RN, and **Nashat Gabrail, MD**, both in **Gabraail Cancer Center, Canton, OH: Phase 3 Study Comparing the efficacy and safety of sustained- release Granisetron (APF530) and Palo-nosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving moderately or highly emeto-genic chemotherapy.** ONS 2014 Abstract #34. *Oncology Nursing Forum* Volume 41 Number 2 March 2014
- Naumann RW¹, Coleman RL², Burger RA⁴, Sausville EA⁵, Kutarska E⁶, Ghamande SA⁸, **Gabraail NY⁹**, Depasquale SE¹⁰, Nowara E⁷, Gilbert L¹¹, Gersh RH¹², Teneriello³ MG, Harb WA¹³, Konstantinopoulos PA¹⁵, Penson RT¹⁶, Symanowski JT¹, Lovejoy CD¹⁴, Leamon CP¹⁴, Morgenstern DE¹⁴, Messmann RA¹⁴.; (1)Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; (2) Anderson Cancer Center, University of Texas, Houston; (3)Texas Oncology, Austin, TX;(4) Fox Chase Cancer Center, Philadelphia, PA; (5) Greenebaum Cancer Center, University of Maryland, Baltimore, MD;(6) Centrum Onkologii Ziemi Lubelskiej, Lubland; (7) Instytut im. Marii Skłodowskiej-Curie, Gliwice, Poland;(8) Georgia Health Sciences University, Augusta, GA;(9) **Gabraail Cancer Center, Canton, OH**;(10) Chattanooga's Program in Women's Oncology, Chattanooga, TN;(11) McGill University Health Centre, Montreal, Quebec, Canada; (12) Cancer Care Northwest, Spokane, WA; (13), Horizon Oncology Research, Lafayette; (14), Endocyte, West Lafayette, IN; (15) Beth Israel Deaconess Medical Center; and (16) Dana-Farber Cancer Center, Massachusetts General Hospital, Boston, MA: **PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.** *J Clin Oncol.* 10;31(35):4400-6. Dec 2013
- Christine I. Chen, MD¹, Martin Gutierrez, MD², Peter de Nully Brown³, **Nashat Gabrail, MD⁴**, Rachid Baz, MD⁵, Donna E. Reece, MD⁶, Michael Savona, MD⁷, Suzanne Trudel, MD, MSC, FRCPC⁸, David S. Siegel, MD, PhD⁹, Morten Mau-Sorensen, MD¹⁰, John Kuruvilla, MD, FRCPC¹¹, John C. Byrd, MD¹², Sharon Shacham, PhD, MBA¹³, Tami Rashal, MD¹³, Cindy YF Yau, MSc, CCRP¹⁴, Dilara McCauley, PhD¹⁵, Jean-Richard Saint-Martin¹³, John McCartney, PhD¹³, Yosef Landesman, PhD¹³, Boris Klebanov¹³, Greg Pond, PhD¹⁴, Amit M. Oza, MBBS, MD¹⁴, Michael Kauffman, MD, PhD¹³ and Mansoor R Mirza, MD¹⁶, ¹Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, ²Hackensack University Medical Centre, Hackensack, NJ, ³Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴**Gabraail Cancer Center, Canton, OH**, ⁵Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, ⁶Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁷Sarah Cannon Research Institute, Nashville, TN, ⁸Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ⁹John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Department of Oncology Rigshospitalet, Copenhagen, Denmark, ¹¹Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, ¹²The Ohio State University, Columbus, OH, ¹³Karyopharm Therapeutics Inc, Natick, MA, ¹⁴Ozmosis Research Inc, Toronto, ON, Canada, ¹⁵Karyopharm Therapeutics, Boston, MA, ¹⁶Rigshospitalet, Copenhagen, Denmark: **Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM).** ASH 2013, Abstract 1942; Poster , December 7, 2013
- Christopher J. Walker¹, Joshua J. Oaks¹, Ramasamy Santhanam^{1,2}, Paolo Neviani^{1,3}, Jason G. Harb¹, Gregory Ferencak¹, Justin J. Ellis¹, Yosef Landesman⁴, Ann-Kathrin Einfeld¹, **Nash Y. Gabrail⁵**, Carrie L. Smith⁵, Michael A. Caligiuri^{2,3}, Peter Hokland⁶, Denis Claude Roy⁷, Alistair Reid⁸, Dragana Milojkovic⁸, John M. Goldman⁸, Jane Apperley⁸, Ramiro Garzon^{2,3}, Guido Marcucci^{2,3}, Sharon Shacham⁴, Michael G. Kauffman⁴, and Danilo Perrotti^{1,3,8} ¹Human Cancer

Genetics Program, Department Molecular Virology Immunology and Medical Genetics, ²Department of Internal Medicine, and ³Comprehensive Cancer Center, The Ohio State University, Columbus, OH; ⁴Karyopharm Therapeutics Incorporated, Natick MA; ⁵**Gabrail Cancer Center, Canton, OH**; ⁶Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; ⁷Department of Hematology-Oncology, Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, QC, Canada; and ⁸Department of Hematology, Hammersmith Hospital, Imperial College London, London, United Kingdom: **Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph⁺ leukemias.** *Blood*. Volume 122: Number 17. October 24, 2013

- Richard Harrop, Franklin Chu, **Nashat Gabrail**, Sandy Srinivas, Daniel Blount & Anna Ferrari: **Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.** *Cancer Immunology, Immunotherapy*. Volume 62: Number 8. August 2013
- Guillermo Garcia-Manero¹, Elias Jabbour¹, Gautam Borthakur¹, Stefan Faderl¹, Zeev Estrov¹, Hui Yang¹, Sirisha Maddipoti¹, Lucy A. Godley², **Nashat Gabrail**³, Jesus G. Berdeja⁴, Ahmed Nadeem⁵, Laurent Kassalow⁶ and Hagop Kantarjian¹; (1)The University of Texas MD Anderson Cancer Center, Houston, TX; (2)The University of Chicago, Chicago, IL; (3)**Gabrail Cancer Center, Canton, OH**; (4)Sarah Cannon Research Institute, Nashville, TN; (5)Landmark Medical Center, Woonsocket, RI; and (6) Eisai Pharmaceuticals, Woodcliff Lake, NJ: **Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.** *Journal of Clinical Oncology* Volume 31: Number 20. July 10 2013
- Donald R. Taylor, Allen W. Burton, **Nashat Y. Gabrail**, Didier Mayeur, Philippe Poulain, Alain Serrie, Luis M. Torres: **Letter to the Editor: Pharmacokinetics of Non-Intravenous Formulations of Fentanyl.** *Clinical Pharmacokinetics*, Volume 52: Issue 5, pp 397-398. Apr 2013
- Feng Liu¹, Moshe Talpaz², Animesh Pardanani³, Catriona Jamieson⁴, **Nashat Gabrail**⁵, Ayalew Tefferi³, Tianlei Lei¹, Rita Greco¹, Francisco Adrian¹, Nikki Daskalakis¹, Claudia Lebedinsky¹, Pamela Cohen¹, and Donald Bergstrom¹, ¹Sanofi Oncology, Cambridge, MA; ²University of Michigan, Ann Arbor, MI; ³Mayo Clinic, Rochester, MN; ⁴Moore's UCSD Cancer Center, La Jolla, CA; ⁵**Gabrail Cancer Center, Canton, OH: Abstract LB-294: Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay.** *Cancer Research*. Volume 73: Issue 8, Supplement 1. April 15, 2013
- Feng Liu¹, Moshe Talpaz², Animesh Pardanani³, Catriona Jamieson⁴, **Nashat Gabrail**⁵, Ayalew Tefferi³, Tianlei Lei¹, Rita Greco¹, Francisco Adrian¹, Nikki Daskalakis¹, Claudia Lebedinsky¹, Pamela Cohen¹, Donald Bergstrom¹. ¹Sanofi Oncology, Cambridge, MA; ²University of Michigan, Ann Arbor, MI; ³Mayo Clinic, Rochester, MN; ⁴Moore's UCSD Cancer Center, La Jolla, CA; ⁵**Gabrail Cancer Center, Canton, OH : LB-294: Determination of JAK2V617F allele burden in a phase II study of patients with myelofibrosis treated with SAR302503 using a sensitive and robust allele-specific qPCR assay.** April 9th, 2013
- Adrian S Dobs, Ralph V Boccia, Christopher C Croot, **Nashat Y Gabrail**, James T Dalton, Michael L Hancock, Mary A Johnston, Mitchell S Steiner: **Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial.** *The Lancet*. Volume 14: Number 4. Pg 335-345. April 2013
- **Nashat Y. Gabrail**, Carrie L. Smith; **Gabrail Cancer Center, Canton, Ohio: Preliminary**

evidence of activity of Pralatrexate in relapsed/refractory Ovarian Cancer. ASCO 2012, Abstract#15557; *J Clin Oncol* 30, 2012 (suppl; abstr e15557). June 2012

- Veena Charu¹, Rebecca Clark-Snow², **Nashat Gabrail**³, Ronald Yanagihara⁴, Martin J. Rosenberg⁵, Erin O'Boyle⁶, John Barr⁶ ¹Pacific Cancer Medical Center, Inc., Anaheim, CA; ²University of Kansas Cancer Center, Westwood, KS; ³**Gabrail Cancer Center, Canton, OH**; ⁴Ronald Yanagihara, MD, Gilroy, CA; ⁵ MAJARO InfoSystems, Santa Clara, CA; ⁶A.P.Pharma, Redwood City, CA, USA: **Patient Satisfaction with Control of Emesis Following Chemotherapy: Comparison of APF530, a Subcutaneous Extended-Release Formulation of Granisetron, Versus Intravenous Palonosetron.** MASCC, Poster, June 2012
- Ravi Vij¹, Michael Wang², Jonathan L. Kaufman³, Sagar Lonial³, Andrzej J. Jakubowiak⁴, A. Keith Stewart⁵, Vishal Kukreti⁶, Sundar Jagannath⁷, Kevin T. McDonagh⁸, Melissa Alsina⁹, Nizar J. Bahlis¹⁰, Frederic J. Reu¹¹, **Nashat Y. Gabrail**¹², Andrew Belch¹³, Jeffrey V. Matous¹⁴, Peter Lee¹⁵, Peter Rosen¹⁶, Michael Sebag¹⁷, David H. Vesole¹⁸, Lori A. Kunkel¹⁹, Sandra M. Wear²⁰, Alvin F. Wong²¹, Robert Z. Orlowski², and David S. Siegel¹⁸; ¹Washington University School of Medicine, St Louis, MO; ²MD Anderson Cancer Center, Houston, TX; ³Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; ⁴University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; ⁵Mayo Clinic, Scottsdale, AZ; ⁶University of Toronto Princess Margaret Hospital, Toronto, ON; ⁷Mount Sinai Medical Center, New York, NY; ⁸University of Kentucky College of Medicine, Lexington, KY; ⁹H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL; ¹⁰Tom Baker Cancer Centre, University of Calgary, Calgary, AB; ¹¹Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; ¹²**Gabrail Cancer Center, Canton, OH**; ¹³University of Alberta Cross Cancer Institute, Edmonton, AB; ¹⁴Colorado Blood Cancer Institute, Denver, CO; ¹⁵Tower Cancer Research Foundation, Beverly Hills, CA; ¹⁶Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA; ¹⁷Royal Victoria Hospital, Montreal, QC; ¹⁸John Theurer Cancer Center at Hackensack University, Hackensack, NJ; ¹⁹Independent consultant, San Francisco, CA; ²⁰Multiple Myeloma Research Consortium, Norwalk, CT; and ²¹Onyx Pharmaceuticals, South San Francisco, CA: **An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma.** *Blood*. Volume 119: June 14 2012
- Razelle Kurzrock¹, **Nash Gabrail**⁴, Chandtip Chandhasin¹, Stacy Moulder², Carrie Smith⁴, Andrew Brenner³, Kamalesh Sankhala³, Alain Mita³, Kelly Elian⁵, Danielle Bouchard⁵, and John Sarantopoulos³, Departments of ¹Investigational Cancer Therapeutics (Phase I Program) and ²Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas; ³Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, Texas; ⁴**Gabrail Cancer Center, Canton, Ohio**; and ⁵Angiochem Inc., Montreal, Québec, Canada: **Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors.** *Molecular Cancer Therapeutics*, February 2012
- Alexander Spira¹, Nicholas Iannotti², Michael Savin³, Marcus Neubauer⁴, Nashat Gabrail⁵, Ronald Yanagihara⁶, Edith Zang⁷, Patricia Cole⁷, Dale Shuster⁷, Asha Das⁷ ¹Virginia Cancer Specialists, Fairfax, VA, ²Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL, ³Texas Oncology, Texas Cancer Center at Medical City, Dallas, TX, ⁴Kansas City Cancer Center, Kansas City, MO, ⁵Gabrail Cancer Center, Canton, OH, ⁶St Louise Hospital, Gilroy, CA, ⁷Eisai Inc., Woodcliff Lake, NJ: **A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer.** *Clinical Lung Cancer*. Volume 13: Issue 1. Pages 31-38. January 2012
- Lowell B. Anthony, MD,¹ **Nashat Y. Gabrail, MD**,² Hassan Ghazal, MD,³ Donald V.

Woytowicz, MD,⁴ Marshall S. Flam, MD,⁵ Anibal Drelichman, MD,⁶ David M. Loesch, MD,⁷ Demi A. Niforos, MS,⁸ and Antoinette Mangione, MD, PharmD⁹; for the Iron Sucrose Study Group*; (1) Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA; (2) Nashat Cancer Center, Canton, OH; (3) Kentucky Cancer Clinic, Hazard, KY; (4) Florida Cancer Specialists, Fort Myers, FL; (5) Hematology/Oncology Group of Fresno, Fresno, CA; (6) Newland Medical Associates, Southfield, MI; (7) Oncology/Hematology Associates, Indianapolis, IN; (8) AAI Pharma, Inc., Natick, MA; and (9) Luitpold Pharmaceuticals/American Regent, Inc., Norristown, PA: **IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis stimulating agents.** *Community Oncology*. Manuscript; June 29, 2011

- Stewart,¹ JL Kaufman,² AJ Jakubowiak,³ S Jagannath,⁴ V Kukreti,⁵ KT McDonagh,⁶ M Alsina,⁷ NJ Bahlis,⁸ A Belch,⁹ FJ Reu,¹⁰ **NY Gabrail**,¹¹ J Matous,¹² DH Vesole,¹³ RZ Orlowski,¹⁴ L Kunkel,¹⁵ NR Sacks,¹⁶ P Lee,¹⁷ M Sebag,¹⁸ M Wang,¹⁴ R Vij,¹⁹ The Multiple Myeloma Research Consortium²⁰; ¹Mayo Clinic, Scottsdale, AZ; ²Winship Cancer Institute, Atlanta, GA; ³University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; ⁴Mt. Sinai Medical Center, New York, NY; ⁵Princess Margaret Hospital, Toronto, ON, Canada; ⁶University of Kentucky College of Medicine, Lexington, KY; ⁷H. Lee Moffitt Cancer Center, Tampa, FL; ⁸Tom Baker Cancer Centre, Calgary, AB, Canada; ⁹University of Alberta Cross Cancer Institute, Edmonton, AB, Canada; ¹⁰Cleveland Clinic, Cleveland, OH; ¹¹**Gabraail Cancer Center**, Canton, OH; ¹²Rocky Mountain Cancer Center, Denver, CO; ¹³John Theurer Cancer CeHackensack, NJ; ¹⁴MD Anderson Cancer Center, Houston, TX; ¹⁵Independent Consultant, San Francisco, CA; ¹⁶Onyx Pharmaceuticals, South San Francisco, CA; ¹⁷Tower Cancer Research Foundation, Beverly Hills, CA; ¹⁸Royal Victoria Hospital, Montreal, QC, Canada; ¹⁹Washington University School of Medicine, St. Louis, MO; ²⁰Norwalk, CT: **Carfilzomib produces a high single-agent response rate in patients with bortezomib-naïve relapsed multiple myeloma: Updated interim results from the PX-171-004 study**AK. 47th American Society of Clinical Oncology Annual Meeting; June 3–7, 2011; Chicago, IL
- M Wang,¹ W Bensinger,² T Martin,³ M Alsina,⁴ D Siegel,⁵ **N Gabrail**,⁶ P Hari,⁷ S Singhal,⁸ R Vescio,⁹ S Assouline,¹⁰ L Kunkel,¹¹ M Vallone,¹² A Wong,¹² R Niesvizky¹³ ¹MD Anderson Cancer Center, Houston, TX; ²Fred Hutchinson Cancer Research Center, Seattle, WA; ³University of California, San Francisco, CA; ⁴H. Lee Moffitt Cancer Center, Tampa, FL; ⁵John Theurer Cancer Center, Hackensack, NJ; ⁶**Gabraail Cancer Center, Canton, OH**; ⁷Medical College of Wisconsin, Milwaukee, WI; ⁸Northwestern University School of Medicine, Chicago, IL; ⁹Cedars Sinai Medical Center, Los Angeles, CA; ¹⁰Jewish General Hospital, Montreal, QC, Canada; ¹¹Independent Consultant, San Francisco, CA; ¹²Onyx Pharmaceuticals, Inc., South San Francisco, CA; ¹³Weill Cornell Medical College, New York, NY: **Interim results from PX-171-006, a phase 2 multicenter dose-expansion study of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed and/or refractory multiple myeloma.** 47th American Society of Clinical Oncology Annual Meeting; June 3–7, 2011; Chicago, IL
- Alberto Bessudo¹, Johanna C. Bendell², **Nashat Y. Gabrail**³, Mikhail V. Kopp⁴, Lothar Muller⁵, Lowell L. Hart⁶, Vladimir I. Vladimirov⁷, Amitkumar U. Pande⁸, Igor Gorbachevsky⁸, Cathy Eng⁹ ¹Pacific Oncology Hematology Associates, Encinitas, CA; ²Sarah Cannon Research Institute, Nashville, TN; ³**Gabraail Cancer Center, Canton, OH**; ⁴Samara Regional Clinical Oncology Dispensary, Samara, Russia; ⁵Onkologische Schwerpunktpraxis Leer-Emden, Leer, Germany; ⁶Florida Cancer Specialists, Fort Myers, FL; ⁷State Medical Institution Pyatigorsk, Pyatigorsk, Russia; ⁸Daiichi Sankyo, Inc., Edison, NJ; ⁹University of Texas M. D. Anderson Cancer Center, Houston, TX: **Phase I Results of the Randomized, Placebo-Controlled, Phase I/II Study of the Novel Oral C-MET Inhibitor, Tivantinib (ARQ 197), Irinotecan (CPT-11), and Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer Who Have Received Front-line Systemic Therapy.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago,

Illinois

- ¹Ruben Niesvizky, ²Ian Flinn, ³Robert Rifkin, ⁴**Nashat Gabrail**, ⁵Veena Charu, ⁶Billy Clowney, ⁷James Essell, ⁸Yousuf Gaffar, ⁹Thomas Warr, ¹⁰Rachel Neuwirth, ¹⁰Deyanira Corzo, ¹¹James Reeves; ¹Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, ²Sarah Cannon Research Institute, Nashville, TN, USA, ³Rocky Mountain Cancer Center, US Oncology, Denver, CO, USA, ⁴**Gabrail Cancer Center, Canton, OH, USA**, ⁵Pacific Cancer Medical Center, Anaheim, CA, USA, ⁶Santee Hematology/Oncology, Sumter, SC, USA, ⁷Oncology Hematology Care Inc., Cincinnati, OH, USA, ⁸St. Joseph Medical Center, Towson, MD, USA, ⁹Clinic Cancer Care, Great Falls, MT, USA, ¹⁰Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, ¹¹Florida Cancer Specialists, Fort Myers, FL, USA: **Analysis of Response, PFS, and Safety After Bortezomib-Based Induction Regimens and Weekly Bortezomib Maintenance Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (pts) Ineligible for Transplant in the Phase 3b UPFRONT Study.** International Myeloma Workshop, May 3-6 2011, Paris, France
- E.B. Garon¹, F. Kabbinavar¹, J. Neidhart², J. D. Neidhart², **N. Gabrail**³, M. Ribeiro de Oliveira⁴, SP. Lu⁵, J. Balkissoon⁵; ¹UCLA Medical Center, Los Angeles, CA; ²San Juan Oncology Associates, Farmington, NM; ³**Gabrail Cancer Center; Canton, OH**; ⁴Northwest Medical Specialties, Tacoma, WA; ⁵OXiGENE, Inc., South San Francisco, CA: **Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois
- R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, **N. Y. Gabrail**, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann; Blumenthal Cancer Center Carolinas Medical Center, Charlotte, NC; University of Texas M. D. Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Columbia University Cancer Center, New York, NY; Karmanos Cancer Institute/Wayne State University, Detroit, MI; University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD; Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland; Medical College of Georgia, Augusta, GA; **Gabrail Cancer Center, Canton, OH**; Chattanooga's Program in Women's Oncology, Chattanooga, TN; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; McGill University Health Centre, Montreal, QC, Canada; Willamette Valley Cancer Center, Eugene, OR; Cancer Center of Northwest, Spokane, WA; US Oncology, The Woodlands, TX; Horizon Oncology Center, Lafayette, IN; Beth Israel Deaconess Medical Center, Boston, MA; Nevada Cancer Institute, Las Vegas, NV; Endocyte, Inc., West Lafayette, IN: **PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois, *J Clin Oncol* 29: 2011 (suppl; abstr 5045). June 2011
- K. Ankrom, C.L. Smith, **N.Y. Gabrail**; Mount Union University, Alliance, OH; **Gabrail Cancer Center, Canton, OH: Incidence of Radiation recall in a community cancer center.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr e19640) June 2011
- ¹**N. Y. Gabrail**, ²S. M. Weinstein, ³A. W. Burton; ¹**Gabrail Cancer Center, Canton, OH**; ²Huntsman Cancer Institute, ³University of Utah, Salt Lake City, UT; University of Texas M. D. Anderson Cancer Center, Houston, TX: **Long-term nasal tolerability of fentanyl pectin nasal spray in breakthrough pain in cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago,

Illinois, *J Clin Oncol* 29: 2011 (suppl; abstr e19604) June 2011

- ¹David B. Agus, ²Walter M. Stadler, ³Daniel Shevrin, ⁴John Gullo, ⁵Lowell Hart, ⁶Gary R. MacVicar, ⁷Omid Hamid, ⁸**Nashat Gabrail**, ⁹John Hainsworth, ¹⁰Mitchell Gross, ¹¹Jingyuan Wang, ¹¹Laura DeLeon, ¹²David MacLean, and Robert Dreicer; ¹University of Southern California Keck School of Medicine, ²University of Chicago Medical Center, ³NorthShore University HealthSystem, ⁴Hematology/Oncology Associates, ⁵Florida Cancer Specialists, ⁶Northwestern University Feinberg School of Medicine, ⁷The Angeles Clinic & Research Institute, ⁸**Gabrail Cancer Center**, ⁹Sarah Cannon Cancer Research Institute, ¹⁰Westside Prostate Cancer Center, ¹¹Millennium Pharmaceuticals Inc, ¹²Cleveland Clinic: **Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase 1/2 study.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois, June 2011
- M. J. Higgins, **N. Y. Gabrail**, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh, J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. Ryan; Massachusetts General Hospital, Boston, MA; **Gabrail Cancer Center, Canton, OH**; Indiana University Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Cambridge, MA; Huntsman Cancer Institute, Salt Lake City, UT: **A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr TPS119). Poster. June 2011
- G. J. Riely, S. N. Gettinger, R. G. Stoller, **N. Y. Gabrail**, G. K. Dy, G. J. Weiss, C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. Gray; Memorial Sloan-Kettering Cancer Center, New York, NY; Yale University School of Medicine, New Haven, CT; University of Pittsburgh Cancer Center, Pittsburgh, PA; **Gabrail Cancer Center, Canton, OH**; Roswell Park Cancer Institute, Buffalo, NY; Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ; Infinity Pharmaceuticals, Inc., Cambridge, MA; University of Pittsburgh, Pittsburgh, PA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL: **Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).** 2011 ASCO Annual Meeting. June 3-7, 2011. Chicago, Illinois. *J Clin Oncol* 29: 2011 (suppl; abstr 7516), Poster, June 2011
- DS Siegel,¹ JL Kaufman,² M Wang,³ T Martin,⁴ S Jagannath,⁵ R Niesvizky,⁶ FJ Reu,⁷ M Alsina,⁸ A Badros,⁹ **NY Gabrail**,¹⁰ V Kukreti,¹¹ S Singhal,¹² D Kotlovker,¹³ D Bomba,¹³ AL Hannah,¹³ R Vij¹⁴: ¹John Theurer Cancer Center, Hackensack, NJ, USA; ²Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; ³MD Anderson Cancer Center, Houston, TX, USA; ⁴University of California San Francisco, San Francisco, CA, USA; ⁵Mount Sinai Medical Center, New York, NY, USA; ⁶Weill Cornell Medical College, New York, NY, USA; ⁷Taussig Cancer Center - Cleveland Clinic, Cleveland, OH, USA; ⁸H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁹University of Maryland Greenebaum Cancer Center, Baltimore MD, USA; ¹⁰**Gabrail Cancer Center, Canton, OH, USA**; ¹¹Princess Margaret Hospital, Toronto, ON, Canada; ¹²Northwestern University School of Medicine, Chicago, IL, USA; ¹³Onyx Pharmaceuticals, South San Francisco, CA, USA; ¹⁴Washington University School of Medicine, St. Louis, MO, USA: **A summary of safety data achieved with long-term carfilzomib treatment in patients with relapsed and/or refractory multiple myeloma.** 16th Congress of European Hematology Association;; London, UK. June 9–12, 2011
- **Nashat Gabrail, MD**¹, Eric Sandler, MD², Veena Charu, MD³, Nick Anas, MD⁴, Eduardo Lim, MD⁵, Martha Blaney, PharmD⁶, Mark Ashby, PhD⁶, Barbara Gillespie, MD⁷, Susan Begelman, MD⁶ **Gabrail Cancer Center , Canton, OH**, ²Nemours Children’s Clinic, Jacksonville, FL,

³Pacific Cancer Medical Center, Inc Anaheim, CA, ⁴Children's Hospital of Orange County, Orange, CA, ⁵Private Practice, Los Angeles, CA, ⁶Genetech, Inc South San Francisco, CA, ⁷Quintiles, Inc., Morrisville, NC: **TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters.** *Journal of Vascular and Interventional Radiology.* Volume 21: Issue 12. Pages 1852-1858. December 2010

- Russell K. Portenoy^a, Allen W. Burton^b, **Nashat Gabrail^c**, Donald Taylor^d, on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group, ^a Beth Israel Medical Center, New York, NY, USA, ^b The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, ^c **Gabrail Cancer Center, Canton, OH, USA,** ^d Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA: **A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.** *Pain* Volume 151: Issue 3 Pages 617-624. December 2010
- Ruben Niesvizky¹, Ian Flinn², Robert Rifkin³, **Nashat Gabrail⁴**, Veena Charu⁵, Billy Clowney⁶, James Essell⁷, Yousuf Gaffar⁸, Thomas Warr⁹, Rachel Neuwirth¹⁰, Deyanira Corzo¹⁰, and James Reeves¹¹Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; ²Sarah Cannon Research Institute, Nashville, TN; ³Rocky Mountain Cancer Center, US Oncology, Denver, CO; ⁴**Gabrail Cancer Center, Canton, OH;** ⁵Pacific Cancer Medical Center, Anaheim, CA; ⁶Santee Hematology/Oncology, Sumter, SC; ⁷Oncology Hematology Care Inc., Cincinnati, OH; ⁸Alliance Hematology Oncology, Westminster, MD; ⁹Clinic Cancer Care, Great Falls, MT; ¹⁰Millennium Pharmaceuticals, Inc., Cambridge, MA; ¹¹Florida Cancer Specialists, Bonita Springs, FL: **Patient-Reported Quality of Life in Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results from the Phase 3b UPFRONT Study.** ASH; Abstract #3026. Poster. December, 2010
- Ruben Niesvizky¹, Ian Flinn², Robert Rifkin³, **Nashat Gabrail⁴**, Veena Charu⁵, Billy Clowney⁶, James Essell⁷, Yousuf Gaffer⁸, Thomas Warr⁹, Rachel Neuwirth¹⁰, Deyanira Corzo¹⁰, and James Reeves¹¹; ¹Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; ²Sarah Cannon Research Institute, Nashville, TN; ³Rocky Mountain Cancer Center, US Oncology, Denver, CO; ⁴**Gabrail Cancer Center, Canton, OH;** ⁵Pacific Cancer Medical Center, Anaheim, CA; ⁶Santee Hematology/Oncology, Sumter, SC; ⁷Oncology Hematology Care Inc., Cincinnati, OH; ⁸Carroll County Cancer Center, Westminster, MD; ⁹Clinic Cancer Care, Great Falls, MT; ¹⁰Millennium Pharmaceuticals, Inc., Cambridge, MA; ¹¹Florida Cancer Specialists, Fort Myers, FL: **Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.** ASH, Abstract # 619. Poster. December, 2010
- Ravi Vij, MBBS, MD¹, Jonathan L. Kaufman, MD², Andrzej J Jakubowiak, MD, PhD³, A. Keith Stewart, MBChB⁴, Sundar Jagannath, MD⁵, Vishal Kukreti, MD, FRCPC⁶, Kevin T. McDonagh, MD⁷, Melissa Alsina, MD⁸, Nizar J Bahlis, MD⁹, Andrew Belch, MD¹⁰, Frederic J. Reu, MD¹¹, **Nashat Y Gabrail, MD¹²**, Jeffrey Matous, MD¹³, David H. Vesole, MD, PhD¹⁴, Robert Z. Orlowski, MD, PhD¹⁵, Mai H. Le, MD¹⁶, Peter Lee, MD, PhD¹⁷, Michael Wang, MD¹⁸ and The Multiple Myeloma Research Consortium (MMRC)¹⁹; ¹Division of Oncology, Washington University School of Medicine, Saint Louis, MO; ²Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; ³University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; ⁴Mayo Clinic in Arizona, Scottsdale, AZ; ⁵Multiple Myeloma Program, Mount Sinai Medical Center, New York, NY; ⁶Div. of Hematology/Oncology, Princess Margaret Hospital, Toronto, ON, Canada; ⁷University of Kentucky, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY; ⁸H. Lee Moffitt Cancer Center, Tampa, FL; ⁹Division of

Hematology, University of Calgary, Calgary, AB, Canada; ¹⁰Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; ¹¹Taussig Cancer Center, Cleveland, OH; ¹²**Gabrail Cancer Center Research, Canton, OH**; ¹³Rocky Mountain Cancer Ctr., Denver, CO; ¹⁴Hackensack University Medical Center, Hackensack, NJ; ¹⁵Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX; ¹⁶Clinical Development, Onyx Pharmaceuticals, Emeryville, CA; ¹⁷Tower Cancer Research Foundation, Beverly Hills, CA; ¹⁸MD Anderson Cancer Center, Houston, TX; ¹⁹The Multiple Myeloma Research Consortium, Norwalk, CT: **Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even in High-risk Patients.** ASH, Abstract #1938. Poster. December 4, 2010

- Sundar Jagannath, MD¹, Ravi Vij, MBBS, MD², Janathan L. Kaufman, MD³, Thomas Martin, MD⁴, Ruben Niesvizky, MD⁵, **Nashat Y Gabrail MD⁶**, Melissa Alsina, MD⁷, Alvin Wong PharmD⁸, Mai H. Le, MD⁹, Leanne McCulloch, PharmD⁸, Alison Hannah, MD⁸, Michael Kauffman, MD, PhD⁸ and Samuel diCapua Siegal, MD, PHD¹⁰; ¹Multiple Myeloma Program, Mount Sinai Medical Center, New York, NY, USA, ²Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA, ³Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA, ⁴University of San Francisco, San Francisco, ⁵Medicine and Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA, ⁶**Gabrail Cancer Center Research, Canton, OH, USA**, ⁷Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, USA, ⁸Onyx Pharmaceuticals, Emeryville, CA, USA, ⁹Clinical Development, Onyx Pharmaceuticals, Emeryville, CA, USA, ¹⁰John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA: **Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM).** ASH, Abstract #1953. Poster. December 4th, 2010
- Michael Wang ¹ Ruben Niesvizky ² Robert Orlowski ¹ Melissa Alsina ³ Tom Martin ⁴ Seema Singhal ⁵ **Nashat Gabrail ⁶** Marcy Vallone ⁷ Lynne A. Bui ⁷ Michael Kauffman ⁷ William Bensinger ⁸ (1) MD Anderson Cancer Center, Houston, TX (2) Weill Cornell Medical College, New York, NY (3) H. Lee Moffitt Cancer Center, Tampa, FL (4) UCSF, San Francisco, CA (5) Northwestern University School of Medicine, Chicago, IL (6) **Gabrail Cancer Center, Canton, OH** (7). Onyx Pharmaceuticals, Emeryville, CA (8) Fred Hutchinson Cancer Research Center, Seattle, WA: **Phase 1b Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).** Lymphoma & Myeloma 2010. Abstract # 37.00. Poster. October 21-23, 2010
- Tom Martin ¹ Ruben Niesvizky ² Michael Wang ³ Robert Orlowski ³ Melissa Alsina ⁴ Seema Singhal ⁵ **Nashat Gabrail ⁶** Marcy Vallone ⁷ Lynne Bui ⁷ Michael Kauffman ⁷ William Bensinger ⁸; 1. UCSF, San Francisco, CA 2. Weill Cornell Medical College, New York, NY 3. MD Anderson Cancer Center, Houston, TX 4. H. Lee Moffitt Cancer Center, Tampa, FL 5. Northwestern University School of Medicine, Chicago, IL 6. **Gabrail Cancer Center, Canton, OH** 7. Onyx Pharmaceuticals, Emeryville, CA 8. Fred Hutchinson Cancer Research Center, Seattle, WA: **Phase 2 Multicenter Dose Expansion Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).** Lymphoma & Myeloma 2010. Abstract # 41.00. Poster. October 21-23, 2010
- David Siegel,¹ Michael Wang,² Jonathan Kaufman,³ Andrzej Jakubowiak,⁴ Sundar Jagannath,⁵ A. Keith Stewart,⁶ Vishal Kukreti,⁷ Kevin McDonagh,⁸ Nizar Bahlis,⁹ Frederic Reu,¹⁰ Melissa Alsina,¹¹ **Nashat Gabrail,¹²** Andrew Belch,¹³ Jeffrey Matous,¹⁴ Mai H. Le,¹⁵ Ravi Vij,¹⁶ The Multiple Myeloma Research Consortium (MMRC)¹⁷; ¹Hackensack University Medical Center, Hackensack, NJ; ²MD Anderson Cancer Center, Houston, TX; ³Winship Cancer Institute-Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; ⁴University of Michigan Comprehensive Cancer Center, Michigan, MI; ⁵Mt. Sinai Medical

Center, New York, NY; ⁶Mayo Clinic, Scottsdale, AZ; ⁷Princess Margaret Hospital, Toronto, Ontario, Canada; ⁸University of Kentucky College of Medicine, Lexington, KY; ⁹Tom Baker Cancer Centre, Calgary, Alberta, Canada; ¹⁰Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; ¹¹H. Lee Moffitt Cancer Center & Research Center, Tampa, FL; ¹²**Gabrail Cancer Center, Canton, OH**; ¹³University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada; ¹⁴Rocky Mountain Blood and Marrow Transplant Program, Denver, CO; ¹⁵Onyx Pharmaceuticals, Inc., Emeryville, CA; ¹⁶Washington University School of Medicine, St. Louis, MO; ¹⁷The Multiple Myeloma Research Consortium, Norwalk, CT: **Results of an Ongoing Open-label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)**. XXXIII World Congress of the International Society of Hematology - Jerusalem, Israel - October 10–13, 2010

- **Nashat Y Gabrail M.D., Gabrail Cancer Center:** Letter to the Editor. **Fighting current trends in Cancer Care.** *Oncologistics*; Volume 9:Issue 2.Summer 2010.
- William Bensinger, MD, Michael Wang, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Tom Martin, MD, Seema Singhal, MD, **Nashat Gabrail, MD**, Marcy Vallone, Michael Kauffman, MD, PhD, Ruben Niesvizky, MD Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center, Tampa, FL; University of California San Francisco, San Francisco, CA; Northwestern University, Chicago, IL; **Gabrail Cancer Center, Canton, OH**; Onyx Pharmaceuticals, Emeryville, CA; Weill Cornell Medical College, New York, NY: **Dose Escalation Study of Carfilzomib + Lenalidomide + LowDose Dexamethasone in Relapsed/Refractory Multiple Myeloma.** ASCO 2010. June 2010
- John Sarantopoulos¹, **Nashat Gabrail**², Stacy Moulder³, Andrew Brenner¹, Carrie Smith², Danielle Bouchard⁴, Kelly Elian⁴, Betty Lawrence⁴, Wendy Churchill⁴, Paula Bento⁴, Dimitri Fitialos⁵, Ann Neale⁶, Jean-Paul Castaigne⁴, Razelle Kurzrock³ ¹Cancer Therapy and Research Center, San Antonio, Texas; ²**Gabrail Cancer Center, Canton, Ohio**; ³MD Anderson Cancer Center, Houston, Texas; ⁴Angiochem Inc., Montreal, Québec, Canada; ⁵Intrinsic Health Sciences Inc., Mississauga, Ontario, Canada; ⁶WinPharm Associates, Danville, California: **ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.** ASCO 2010. Abstract ID #2556. Poster. June 2010
- Razelle Kurzrock, MD¹, **Nash Gabrail, MD**³, Chandtip Chandhasin, PhD¹, Stacy Moulder, MD², Carrie Smith, RN³, Andrew Brenner, MD, PhD⁴, Kamalesh Sankhala, MD⁴, Alain Mita, MD⁴, Kelly Elian, MS⁵, Danielle Bouchard, CCRA⁵, John Sarantopoulos, MD⁴ ¹Department of Investigational Cancer Therapeutics (Phase I Program), ²Department of Breast Medical Oncology, M. D. Anderson Cancer Center, Houston, TX; ³**Gabrail Cancer Center, Canton, OH**; ⁴Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center San Antonio, San Antonio, TX; and ⁵Angiochem Inc., Montreal (Québec), Canada: **SAFETY, PHARMACOKINETICS AND ACTIVITY OF ANG1005, A NOVEL CONJUGATE OF ANGIOPEP-2 AND PACLITAXEL, IN PATIENTS WITH ADVANCED SOLID TUMORS.** ASCO 2010. June 2010
- **N. Gabrail**¹, C. Smith¹, J.Fox². ¹Gabrail Cancer Center, Canton, Ohio, United States, 44718 ²Department of Mathematics and Science, Walsh University, North Canton, Ohio, United States, 44720: **A Unique Community Based Family Cancer Registry.** ASCO 2010, Abstract #1550; *Journal of Clinical Oncology* 28:15s, 2010 (abstr.1550) . Poster, June 2010
- J. Neidhart, J. D. Neidhart; San Juan Oncology Associates, Farmington, New Mexico; **N. Gabrail; Gabrail Cancer Center; Canton, Ohio**; M. Ribeiro de Oliveira; Northwest Medical

Specialties, Tacoma, Washington; SP. Lu, J. Balkissoon; OXiGENE, South San Francisco, California; F. Kabbinavar; E. Garon; UCLA Medical Center, Los Angeles, California: **Updated activity and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial.** ASCO 2010, Poster, June 2010

- B. Garon¹, F. Kabbinavar¹, J. Neidhart², J. D. Neidhart², **N. Gabrail**³, M. Ribeiro de Oliveira⁴, SP. Lu⁵, J. Balkissoon⁵; ¹UCLA Medical Center, Los Angeles, CA; ²San Juan Oncology Associates, Farmington, NM; ³**Gabrail Cancer Center, Canton, OH**; ⁴Northwest Medical Specialties, Tacoma, WA; ⁵OXiGENE, Inc., South San Francisco, CA: **Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Early Analyses of Safety and Efficacy.** ASCO 2010. Poster. June 2010
- William Bensinger, MD,¹ Michael Wang, MD,² Robert Z. Orlowski, MD, PhD,² Melissa Alsina, MD,³ Tom Martin, MD,⁴ Seema Singhal, MD,⁵ **Nashat Gabrail, MD**,⁶ Marcy Vallone,⁷ Michael Kauffman, MD, PhD,⁷ Ruben Niesvizky, MD⁸; ¹Fred Hutchinson Cancer Research Center, Seattle, WA; ²MD Anderson Cancer Center, Houston, TX; ³H. Lee Moffitt Cancer Center, Tampa, FL; ⁴University of California San Francisco, San Francisco, CA; ⁵Northwestern University, Chicago, IL; ⁶**Gabrail Cancer Center, Canton, OH**; ⁷Onyx Pharmaceuticals, Emeryville, CA; ⁸Weill Cornell Medical College, New York, NY: **Dose-escalation Study of Carfilzomib + Lenalidomide + Low-dose Dexamethasone in Relapsed/Refractory Multiple Myeloma.** ASCO 2010. Abstract #8029. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 8029). June 2010
- **Nashat Gabrail**,¹ Allen Burton,² Lukas Radbruch,³ Donald Taylor,⁴ Evangeline Reyes,⁵ and Russell Portenoy⁶ on behalf of the Fentanyl Nasal Spray Study 045 Investigators Group ¹**Gabrail Cancer Center, Canton, Ohio, USA**; ²The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ³RWTH Aachen University, Aachen, Germany; ⁴Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, Georgia, USA; ⁵Compassionate Cancer Care Medical Group, Inc., Riverside, California, USA; ⁶Beth Israel Medical Center, New York, New York, USA: **Long-term Safety, Tolerability, and Acceptability of Fentanyl Pectin Nasal Spray in the Treatment of Breakthrough Cancer Pain.** ASCO 2010. Poster. June 2010
- John Sarantopoulos¹, **Nashat Gabrail**², Stacy Moulder³, Andrew Brenner¹, Carrie Smith², Danielle Bouchard⁴, Kelly Elian⁴, Betty Lawrence⁴, Wendy Churchill⁴, Paula Bento⁴, Dimitri Fitialos⁵, Ann Neale⁶, Jean-Paul Castaigne⁴, Razelle Kurzrock³; ¹Cancer Therapy and Research Center, San Antonio, Texas; ²**Gabrail Cancer Center, Canton, Ohio**; ³MD Anderson Cancer Center, Houston, Texas; ⁴Angiochem Inc., Montreal, Québec, Canada; ⁵Intrinsic Health Sciences Inc., Mississauga, Ontario, Canada; ⁶WinPharm Associates, Danville, California: **ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.** ASCO 2010. Poster. June 2010
- **A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in central venous catheters: TROPICS 1**; oral presentation at the 2010 SIR Annual Scientific Meeting in Tampa, Florida, May 2010.
- Ruben Niesvizky,¹ James Reeves,² Ian Flinn,³ **Nashat Gabrail**,⁴ Robert Rifkin,⁵ Veena Charu,⁶ Billy Clowney,⁷ James Essell,⁸ Thomas Warr,⁹ Rachel Neuwirth,¹⁰ Deyanira Corzo,¹⁰ on behalf of the UPFRONT Study Group ¹Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY; ²Florida Cancer Specialists, Bonita Springs, FL; ³Sarah Cannon Research Institute, Nashville, TN; ⁴**Gabrail Cancer Center**,

Canton, OH; ⁵Rocky Mountain Cancer Centers, US Oncology, Denver, CO; ⁶Pacific Cancer Medical Center, Anaheim, CA; ⁷Santee Hematology/Oncology, Sumter, SC; ⁸Oncology Hematology Care Inc., Cincinnati, OH; ⁹Clinic Cancer Care, Great Falls, MT; ¹⁰Millennium Pharmaceuticals, Inc., Cambridge, MA: **Phase 3b UPFRONT Study: Interim Results from a Community-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.** EHA. Poster. May 25, 2010

- Natasha B. Leigh¹, Luis Raez², Benjamin Besse³, Peter J. Rosen⁴, Fabrice Barlesi⁵, E. Massarelli⁶, **Nashat Gabrail**⁷, Lowell L. Hart⁸, Kathy S. Albain⁹, Lloyd Berkowitz¹⁰, Ostap Melnyk¹¹, Frances A. Shepherd¹, Lars Sternas¹², Judie Ackerman¹², Zhenming Shun¹², Vincent A. Miller^{13*}, Roy S. Herbst⁶; ¹Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada, ²University of Miami Hospital and Clinics, Miami, FL, ³Institut Gustave Roussy, Villejuif, France, ⁴Tower Cancer Research Foundation, Beverly Hills, CA, ⁵Hopital Sainte Marguerite, Marseilles, France, ⁶MD Anderson Cancer Center at the University of Texas, Houston, TX, ⁷**Gabrail Cancer Center, Canton, OH**, ⁸Florida Cancer Specialists, Fort Myers, FL, ⁹Loyola University Medical Center, Maywood, IL ¹⁰Boca Raton Community Hospital, Boca Raton, FL, ¹¹Bay Area Cancer Research Group, Concord, CA, ¹²sanofi-aventis, Bridgewater, NJ, ¹³Memorial Sloan-Kettering Cancer Center, New York, NY: **A Multicenter, Phase 2 Study of VEGF Trap (Aflibercept) in Platinum- and Erlotinib resistant Adenocarcinoma of the Lung.** *J Thorac Oncol.* 3 Nov 2009
- Quinn, David I.¹; Nemunaitis, John²; Fuloria, Jyotsna³; Britten, Carolyn D.⁴; **Gabrail, Nashat**⁵; Yee, Lorrin⁶; Acharya, Milin⁷; Chan, Kai⁸; Cohen, Nadine⁷; Dudov, Assen⁹: **Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.** *Clinical Pharmacokinetics* Volume 48: Number 3. 2009
- **N. Y. Gabrail**, A. W. Burton, E. Reyes, A. Nguyen, D. R. Taylor, on behalf of Fentanyl Nasal Spray Study 043 Investigators Group; **Gabrail Cancer Center, Canton, OH**; University of Texas M. D. Anderson Cancer Center, Houston, TX; Compassionate Cancer Care Medical Group, Inc., Riverside, CA; Compassionate Cancer Care Medical Group, Inc., Fountain Valley, CA; Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA: **Efficacy, tolerability, and speed of onset of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP): A multicenter, placebo-controlled, double-blind, two-phase crossover study.** ASCO 2009. Abstract #9535, *J Clin Oncol* 27:155, 200 (suppl abstract #9535). June 2009
- **Nashat Gabrail, MD**¹, Eric Sandler, MD², Veena Charu, MD^{3*}, Nick Anas, MD^{4*}, Eduardo Lim, MD⁵, Martha Blaney, PharmD^{6*}, Mark Ashby, PhD^{6*}, Barbara S Gillespie, MD^{7*} and Susan M Begelman, MD^{6*1}**Gabrail Cancer Center, Canton, OH**, ²Nemours Children's Clinic, Jacksonville, FL, ³Pacific Cancer Medical Center, Anaheim, CA, ⁴Children's Hospital of Orange County, Los Angeles, CA, ⁵Private Practice, Los Angeles, CA, ⁶Genentech, Inc., South San Francisco, CA, ⁷Quintiles, Inc., Morrisville, NC: **TROPICS 1: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Central Venous Catheters.** ASH 2009, Oral and Poster Abstracts
- RM Buowski,¹ WM Stadler,² RA Figlin,³ JJ Knox,⁴ **N Gabrail**,⁵ DF McDermott,⁶ L Cupit,⁷ WH Miller, Jr.⁸ J Hainesworth,⁹ CW Ryan,¹⁰ on behalf the ARCCS Investigators. ¹ Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio, USA; ²University of Chicago Medical Center, Chicago, IL, USA; ³ City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA; ⁴Princess Margaret Hospital, Toronto, ON, Canada; ⁵**Gabrail Cancer Center, Canton, Ohio, USA**; ⁶ Beth Israel Deaconess Medical Center, Boston, MA, USA; ⁷Bayer Healthcare, West

Haven, CT, USA;⁸Jewish General Hospital, McGill University, Montreal, PQ, Canada; ⁹ Sarah Cannon Research Institute, Nashville, TN, USA; ¹⁰Oregon Health and Science University, Portland, OR, USA: **Safety and Efficacy of Sorafenib in Elderly Patients: A Subset Analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America.** ASCO 2008; Poster. June 2008

- David A. Rizzieri,¹Eric Feldman,² John F. DiPersio,³ **Nashat Gabrail**,⁴ Wendy Stock,⁵ Roger Strair,⁶ Victor M. Rivera,⁷ Maher Albitar,⁸ Camille L. Bedrosian,⁷ and Francis J. Giles⁹ ¹Duke University Medical Center, Durham, North Carolina; ²Weill Medical College of Cornell University, New York, New York; ³Washington University Medical Center, St. Louis, Missouri; ⁴Gabraïl Cancer Center, Canton, Ohio; ⁵University of Chicago Department of Medicine and Cancer Research Center, Chicago, Illinois; ⁶Cancer Institute of New Jersey, New Brunswick, New Jersey; ⁷ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts; ⁸Quest Diagnostics, Nichols Institute, San Juan Capistrano, California; and ⁹University of Texas Health Science Center at San Antonio, San Antonio, Texas: **A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.** *Clin Cancer Research*: Volume 14: Number 9. May 2008
- V. L. Hansen, **N. Gabrail**, J. Levin, R. Bandekar, J. Herrstedt: **Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX); Subgroup analysis from a randomized, double-blind, placebo-controlled phase III trial.** Abstract- No. 359; 2008 Gastrointestinal Cancers Symposium; Category-Colon and Rectum. 2008
- E. Chan, P. O'Dwyer, **N. Gabrail**, L. Zuomei, A. Kalita, M. Trachy-Bourget, M. Tawashi, R. Ward, M. Drouin, H. Hurwitz; **Phase 1 trial of an oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination (combo) with gemcitabine (gem) in patients (pts) with refractory solid tumors.** Gastrointestinal Cancers Symposium; Category-Pancreas, Small Bowel, and Hepatobiliary Tract. Abstract- No.-181. 2008.
- Steven J Cohen, Cornelis J A Punt, Nicholas Iannotti, Bruce H Saidman, Kert D Sabbath, **Nashat Y Gabrail**, Joel Picus, Michael Morse, Edith Mitchell, M Craig Miller, Gerald V Doyle, Henk Tissing, Leon W M M Terstappen, Neal J Meropol: **Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.** *Journal of Clinical Oncology* ; Volume: 26: Issue: 19. Pages: 3213-3221. 2008
- **NY Gabrail**¹, H Eliopoulos², A Coates², X. Zhou², H Xiong², A Hagey² ¹**Gabraïl Cancer Center, Canton, Ohio**; ²Abbott, Abbott Park, Illinois: **Phase ½ Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Alone in Subjects With Advanced or Metastatic Non-small-cell lung Cancer (NSCLC);** IASLC 2007; ASCO 2007.
- Stephan Moll¹, **Nashat Gabrail**², Jim Buchanan³, Mohammad Hirmand³, Michael Levy³, Ralph Zitnik³, ¹University of North Carolina School of Medicine, Chapel Hill, NC; ² **Gabraïl Cancer Center, Canton, Ohio**; ³ Nuvelo, Inc., San Carlos, CA. **Safety and Efficacy of Afimeprase in Subjects with Occluded Central Access Devices: The SONOMA-2 Study.** ASH 2007. Abstract
- Steven M Grunberg MD¹, **Nashat Y Gabrail MD**², Gemma Clark³; ¹University of Vermont, Vermont Cancer Center, 89 Beaumont Avenue, Given E214-E, Burlington, VT 05405, USA; ²**Gabraïl Cancer Center, 4875 Higbee Ave NW, Canton, Ohio 44718, USA**; ³Prostraken, Galabank Business Park, Galashiels, TD1 1QH, UK.: **Phase III trial of transdermal**

granesitron patch (Sancuso) compared with oral granesitron in the management of chemotherapy-induced nausea and vomiting.

MASCC 20th International Annual Symposium, St Gallen, Switzerland. No: 18. Abstract # 031207. Poster 27th-30th June 2007

- David A. Rizzieri, Duke University Medical Center, Durham, NC; Eric Feldman, Weill Medical College of Cornell University, New York, NY; John F DiPersio, Washington University Medical Center, St. Louis, MO; **Nashat Gabrail, Gabrail Cancer Center, Canton, OH**; Wendy Stock, University of Chicago Department of Medicine and Cancer Research Center, Chicago, IL; Roger Strair, Cancer Institute of New Jersey, New Brunswick, NJ; Victor M Rivera, ARIAD Pharmaceuticals, Cambridge, MA; Camille L Bedrosian, Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Francis J. Giles, University of Texas Health Science Center at San Antonio, San Antonio, TX. **A phase 2 trial of AP23573, a novel mTOR inhibitor, in patients with relapsed or refractory hematological malignancies.** Abstract, ASCO 2007.
- J. Knox, Princess Margaret Hospital, Toronto, ONT; R.A. Figlin, City of Hope Comprehensive Cancer Center, Los Angeles, CA; W.M. Stadler, University of Chicago Medical Center, Chicago, IL; D. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; **N. Gabrail, Gabrail Cancer Center, Canton, OH**; W. Miller, McGill University, Montreal, QC; J Hainsworth, Sara Cannon Research Institute, Nashville, TN; C.Ryan, Oregon Health and Science University, Portland, OR; L.Cupit and R Bukowski, Bayer Healthcare, West Haven, CT; Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH: **The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5011
- Spira, N. O. Iannotti, M. A. Savin, M. Neubauer, **N. Y. Gabrail**, R. Yanagihara, K. K. Datta, E. A. Zang, S. Z. Fields, A. Das: **Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC).** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7546
- Lowell B. Anthony, MD, LSUHCS, Stanley S Scott Cancer Center, New Orleans, LA; **Nashat Y Gabrail MD, Gabrail Cancer Center**, Canton, OH; Hassan Ghazal, MD, Kentucky Cancer Clinic, Hazard, KY; Donald V. Woytowitz, MD, Florida Cancer Specialists, Fort Myers, FL; Marshall S. Flam, MD, Hematology Oncology Group of Fresno, Fresno, CA; Anibal Drelichman, MD, Newland Medical Associates, 22301 Foster Winter Drive, Suite 200, Southfield MI; David M. Loesch, MD, Oncology Hematology Associates, Indianapolis, IN; Laszlo Boros, MD, Upstate NY Cancer Research and Education Foundation, Indianapolis, IN; Demi A. Niforos, MS, AAI Pharma, Natick, MA; Antoinette Mangione, MD, Pharm D, Luitpold Pharmaceuticals, Norristown, PA; Robert E. Bellet, MD, Luitpold Pharmaceuticals, Norristown, PA: **A Randomized Open-Label Multi Center Phase III Clinical Trial Comparing Iron Sucrose (Venofer) Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Stimulating Agent Therapy.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 9109.
- D. I. Quinn, J. Nemunaitis, J. Fuloria, C. D. Britten, **N. Y. Gabrail**, L. Yee, M. Acharya, K. C. Chan, P. Bishop, A. P. Dudov: **Open-label study to assess effect of omeprazole (O) on pharmacokinetics of bortezomib (B) in subjects with advanced solid tumors, NHL, or multiple myeloma.** *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 13000.
- Santoro, Istituto Clinico Humanitas, Rozzano, Italy; J. Voglova, Internal Clinic Dept. of Clinical

Haematology, Hradec Kralove, Czech Republic; **N. Gabrail, Gabrail Cancer Center, Canton, OH**; T. Ciuleanu, Oncology Institute, Cluj-Napoca, Romania; M. Liberati, Università degli studi di Perugia Policlinico Mont, Perugia, Italy; B. W. Hancock, Università degli studi di Perugia Policlinico Mont, Perugia, Italy; S. Stromatt, Cell Therapeutics, Inc., Seattle, WA; D. Caballero, Hospital Clinico Servicio, de Hematologia, Salamanca, Spain: **Comparative Trial of Pixantrone + Rituximab vs Single Agent Rituximab in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)**. ASCO 2006. Poster. June 2006

- S. Rosenoff, **N. Gabrail**, R. Conklin, J. Hohnaker, W. Berg, J. Hedrick, G. Warsi, J. Benedetto, W. Zhu, L. Anthony; Oncology and Hematology Associates/US Oncology, Roanoke, VA; **Gabrail Cancer Center, Canton, OH**; Oncology Services of Aberdeen, Aberdeen, SD; Novartis Pharmaceuticals Corporation, East Hanover, NJ; LSUHSC New Orleans, New Orleans, LA: **A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID)**.
- **Nashat Y. Gabrail**, Donald C. Doll, **Gabrail Cancer Center, Canton, OH**, USA; Hematology Oncology, University of Missouri Hospital and Clinics, Columbia, MO, USA: **Alfa Interferon Reverses Bone Marrow Fibrosis in Patients with Myeloproliferative Diseases**. ASH. Poster Session 644-III. Abstract #3424 *Blood*. Volume 102: Issue 11, November 16, 2003.
- **Nashat Y. Gabrail** 1, Chris Dvergsten 2 and Harry Ahdieh 3. **1 Private Practice, Canton, OH, USA**. 2 INC Research, Charlottesville, VA, USA. 3 Endo Pharmaceuticals Inc., Chadds Ford, PA, USA: **Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release inpatients with cancer pain: a randomized controlled study***. *CURRENT MEDICAL RESEARCH AND OPINION*®. VOL. 20: NO. 6. 911–918. 2004
- **N. Y. Gabrail**, C. Dvergsten, T. Ma, A. Frailey, H. Ahdieh; **Private Practice, Canton, OH**, Albania; INC Research, Charlottesville, VA; Endo Pharmaceuticals Inc., Chadds Ford, PA: **Oxymorphone extended-release (ER) provides safe, effective, and rapid analgesia during opioid rotation. Results of a randomized, double-blind, crossover, comparative study with oxycodone controlled-release (CR)**. MASCC/ISOO. 15th International Symposium Supportive Care in Cancer, June 18–21, 2003
- **N. Y. Gabrail**, C. Dvergsten, T. Ma, A. Frailey, H. Ahdieh; Private Practice, Canton, OH, Albania; INC Research, Charlottesville, VA; Endo Pharmaceuticals Inc., Chadds Ford, PA: **Oxymorphone extended-release (ER) provides safe, effective, and rapid analgesia during opioid rotation: Results of a randomized, double-blind, crossover, and comparative study with oxycodone controlled-release (CR)**. ASCO 2003, June 2, 2003.
- **Nashat Y Gabrail: Possible Synergy between Arsenic Trioxide and Cyclosporin A in a patient with Myelodysplastic Syndrome**. Abstract. *Leukemia*. September 2002
- **Nashat Y. Gabrail: Meningeal Lymphoma**. *Oncology News*. Vol. 5: No. 5. May 1996.
- **Nashat Y. Gabrail**: guest editor. **Myeloproliferative diseases**. *Seminars in Oncology*. Vol. 22: No. 4. 1995.
- M.F. Doyle, Stanley Anderson, Carlos Cerrezvelle and **Nashat Y. Gabrail: Sezary Syndrome associated with phenytoin therapy**. *Acta Haematologica*. 92: 204-207. 1994
- **Nashat Y. Gabrail: Management of malignant chordoma**. *Oncology Times*, 1993.
- **Nashat Y. Gabrail**. Barbara Y. Zara: Letter to the Editor. **Pulmonary hemartoma syndrome**.

Chest. Vol. 101: March 1992.

- **Nashat Y. Gabrail:** Letter to the Editor. *Chest* 101:31 March 1992.
- **Nashat Y. Gabrail.** Bruce Harrison, Joung Sunwoo: **Chemo-irradiation induced aorta esophageal fistula.** *Journal of Surgical Oncology*. Vol. 48: p. 9213-9215. 1991.
- **Nashat Y. Gabrail.** Thomas Martin: **Co-existence of essential thrombocythemia and chronic lymphocytic leukemia.** *Acta Haematologica*. Vol. 85: p. 31-33. 1991.
- Michael Doyle. Stanley Anderson. **Nashat Gabrail: Dilantin induced mycosis fungoides.** *Acta Haematologica*. Vol. 85: p. 31-33. 1991
- **Nashat Y. Gabrail.** Barbara Y. Zara: **Pulmonary hemartoma syndrome.** *Chest*, Vol. 97: p. 962-965. April 1990
- **Nashat Y. Gabrail: Acute leukemia after adjuvant chemotherapy for breast cancer.** *Missouri Medicine*. Vol. 86: No. 10, p. 689-690. 1989
- **Nashat Y. Gabrail: High dose chemotherapy with bone marrow transplantation at St. Louis University Hospital.** *Oncology News*. Vol. 4: No. 1. 1989
- **Nashat Y. Gabrail.** John W. Yarbro: Letter to the Editor. **Second cancer after radiation therapy for Hodgkins disease.** *New England Journal of Medicine*. Vol. 319: July 28, 1988
- **Nashat Y. Gabrail, R.R. Abbott: Comparative study of chemotherapy with or without radiation therapy in Stage II Breast Cancer.** Abstract. Proceedings of the 4th Adjuvant Chemotherapy Conference in Tucson, Arizona. 1987
- **Nashat Y. Gabrail.** R.R. Abbott: **Paraganglioma successfully treated with chemotherapy.** Abstract. Proceedings from the 4th Adjuvant Chemotherapy Conference, Tucson, Arizona, 1987.
- **Nashat Y. Gabrail: Severe febrile reaction to isoniazid.** *Chest*. Vol. 91: p. 620-621, April 1987

SCLC CLINICAL TRIAL EXPERIENCE

Nashat Y. Gabrail, **A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy** AMR PH GL 2007 CL 001

Nashat Y. Gabrail **Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)** CA184156

Nashat Y. Gabrail **A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer** M14-361

Nashat Y. Gabrail **INVESTIGATOR-INITIATED, PHASE 2 CLINICAL TRIAL OF SELINEXOR (KPT-330) FOR THE TREATMENT OF POORLY DIFFERENTIATED LUNG AND GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS** GCC-003

Nashat Y. Gabrail **PM1183 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Doxorubicin (DOX) versus Cyclophosphamide (C (DOX) and Vincristine (VCR) (CAV) or -Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (INVESTIGATIONAL MEDICINAL PRODUCT , cyclophosphamide, vincristine C-003-14 001641-89** PM1183-C-00

Nashat Y. Gabrail **Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy** G1T28-02

Nashat Y. Gabrail **A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)** M16-298

Nashat Y. Gabrail **A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)** M16-289

Nashat Y. Gabrail **Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy** G1T28-03

Nashat Y. Gabrail **Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors** SGNLVA-005

Nashat Y Gabrail, M.D.

Nashat Y. Gabrail A PHASE 2, MULTICENTER, OPEN-LABEL, MULTICOHORT STUDY TO ASSESS SAFETY AND EFFICACY OF CC-90011 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH ADVANCED CANCERS CC-90011-ST-002